IOMINVESTCOM
07 Feb 2018
Results GlaxoSmithKline PLC07 February 2018 Issued: Wednesday, 7 February 2018, London U.K. GSK delivers improvements in sales, margins and cash flow in 2017 Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER 2017 financial highlights -- Turnover GBP30.2 billion, +8% AER, +3% CER -- Sales growth across all 3 businesses: Pharmaceuticals GBP17.3 billion, +7% AER, +3%, CER; Vaccines GBP5.2 billion, +12% AER, +6% CER; Consumer Healthcare GBP7.8 billion, +8% AER, +2% CER -- Improved Adjusted Group operating margin of 28.4% (2016: 27.5%). Pharmaceuticals 34.3%; Vaccines 31.9%; Consumer Healthcare 17.7% -- Total EPS 31.4p, after accounting charges of GBP1.6 billion related to US tax reform -- Adjusted EPS 111.8p, +11% AER, +4% CER, in line with 2017 guidance -- 2017 free cash flow of GBP3.4 billion (2016: GBP3.0 billion) -- 23p dividend declared for quarter; 80p for 2017 2018 financial guidance -- 2018 Adjusted EPS Guidance: Growth is subject to uncertainty of timing and impact of possible generic competition to Advair in the US: - In the event of no substitutable generic competitor to Advair in the US, expect 2018 Adjusted EPS growth to be 4 to 7% CER - In the event of a mid-year introduction of a substitutable generic competitor to Advair in the US, expect full year 2018 US Advair sales of around GBP750 million at CER (US$1.30/GBP1) with Adjusted EPS flat to down 3% CER - Both scenarios reflect the benefit of US tax reform with expected 2018 effective tax rate on Adjusted profits of 19-20% -- Continue to expect 80p dividend for 2018 Product and pipeline highlights -- New product sales of GBP6.7 billion, +51% AER, +44% CER, driven by strong performances from Tivicay and Triumeq in HIV, the inhaled Ellipta portfolio and Nucala in Respiratory and meningitis vaccines -- Three key approvals: Shingrix vaccine for shingles; Trelegy Ellipta, once-daily single inhaler triple therapy for COPD; Juluca (dolutegravir and rilpivirine), first 2-drug regimen, once-daily, single pill for HIV -- Preferential recommendation for Shingrix received from US CDC -- Trelegy Ellipta approved in Europe for COPD -- Nucala filed in US for eosinophilic COPD -- Phase III HIV treatment study initiated investigating long-acting 2-drug regimen of cabotegravir plus rilpivirine administered every two months -- In Oncology, Breakthrough Therapy Designation received from FDA for BCMA antibody-drug conjugate for relapsed and refractory multiple myeloma. Positive BCMA data presented at ASH meeting
WhoSparticus
07 Feb 2018
Re: 18+ year low? No, it is (roughly) a five year low. The share price hasn't been this low since late 2012 roughly 5 years ago.
Proverbs 26 vs 5
07 Feb 2018
breakthrough therapy designation from FDA GSK's meningitis B vaccine Bexsero receives breakthrough therapy designation from FDAGlaxoSmithKline's meningitis B vaccine Bexsero received breakthrough therapy designation from the US Food and Drug Administration for prevention of invasive meningococcal disease in children two to ten years of age. Bexsero is the first vaccine in the world to receive the breakthrough therapy designation (BTD) twice. In 2014, Bexsero received BTD for development in the prevention of invasive meningococcal disease in individuals 10-25 years of age and was subsequently granted Accelerated Approval in January 2015. GSK Vaccines Chief Scientist Rino Rappuoli said: 'This designation emphasises the importance of tackling big scientific challenges like meningitis B and breaking new ground in disease prevention through approaches like reverse vaccinology.' GSK Vaccines Chief Medical Officer Dr Thomas Breuer said: 'Thirty-five percent of all meningitis B cases in the US occur in children under 11 years old.' 'This designation is an important step forward in meningococcal prevention and extending the protection provided by this vaccine to a vulnerable age group in the US.' At 9:24am: (LON:GSK) GlaxoSmithKline PLC share price was +5.8p at 1248.6p Story provided by StockMarketWire.com
Haggis48
07 Feb 2018
18+ year low? I last sold GSK in october 2000 at £20.74. There have been no share splits since then. So maybe 5 year low is rather conservative?
FRTEB
06 Feb 2018
Re: 5 year low " guaranteed " Well, it's in black and white, but guaranteed might be overstating it. We'll probably find out tomorrow...
Yee Wo
06 Feb 2018
Re: 5 year low "Future dividend level anyone?" AFAIUI the dividend is guaranteed for 2018, but is subject to review beyond that.
Simbrad
03 Jun 2016
Beaufort note out this morning: "GSK's plan to file the three-drug therapy in the US earlier than schedule is an important step taken by it. The closed triple therapy is a combination of three molecules: fluticasone furoate (FF), an inhaled corticosteroid (ICS), umeclidinium (UMEC), an anti-cholinergic, and vilanterol (VI). The therapy provides GSK an opportunity to recapture its leading position in the COPD market, which has been dented by pricing pressure and competition from other products. Meanwhile, GSK is making good progress on other therapy areas such as HIV vaccines, oncology, cardiovascular and immune inflammation. We believe GSK is moving in the right direction, supported by some world-class assets and technology, to deliver longterm growth and generate stable returns for shareholders." taken off of researchtree
